AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 12 min read$AVR

A test heart valve showed no moderate or severe leaks or valve-related deaths in 22 patients at 30 days.

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day results for its DurAVR THV in 22 patients, showing favorable hemodynamics, no moderate/severe leaks, and no valve-related deaths. The trial is ongoing, with the PARADIGM study comparing DurAVR to other TAVRs. According to the company, the results are promising for long-term outcomes.

Original reporting
stocktitan.net
Published Nov 1, 2026, 7:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 1, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$AVR
Bullish
high confidence
Mentioned
$AVR
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AVRBullishMed
01

Why it matters

The disclosed 30‑day results could accelerate enrollment and investor interest ahead of the pivotal PARADIGM trial readout.

02

Market read

First‑time release of positive early‑stage data for a listed med‑tech firm; may prompt short‑term price movement.

03

What to watch

The device is still investigational and not yet commercialized; regulatory approval remains uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Anteris Technologies (NASDAQ: AVR) is a global healthcare company developing transcatheter heart valves. The DurAVR valve is currently in a pivotal trial against commercial TAVR devices.

Company-level read

Ticker impact

$AVRBullishHigh confidence
Context

Anteris announced 30‑day clinical outcomes for its DurAVR transcatheter heart valve, showing no moderate/severe leaks or valve‑related deaths in 22 patients.

Expected impact

likely upward pressure as the market prices in the favorable safety and hemodynamic results

Evidence & confidence

First‑time disclosure of trial outcomes for a listed med‑tech company; data are materially positive and could influence near‑term valuation.

Market effects

Sector

May raise expectations for other transcatheter aortic valve makers and boost the broader med‑tech sector.

Regional

Positive for US and Australian biotech markets where similar devices are developed.

Global

Limited to investors focused on cardiovascular device innovation.

Counterpoint

What could challenge this read

Early data are limited to 22 patients; larger trials may reveal issues, so caution against over‑optimism.

Key entities

  • company
    Anteris Technologies Global Corp.

    Developer of the DurAVR transcatheter heart valve.

  • clinical_trial
    PARADIGM Trial

    Pivotal randomized study comparing DurAVR to commercial TAVR devices.

Read at source← All news

StoryAnteris reports 30‑day results for medium‑size DurAVR heart valve in 22 patients

Also covered by

1 outlet

Related articles

NOV 1
$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

finance.yahoo.com2 min
NOV 1
$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

mykxlg.com2 min
OCT 20
$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.

finance.yahoo.com2 min